Advances in Stem Cell Therapy for Brain Diseases via the Intranasal Route.
Intranasal delivery
blood-brain barrier
brain targeting
nanotechnology
neurological disorders
stem cells
Journal
Current pharmaceutical biotechnology
ISSN: 1873-4316
Titre abrégé: Curr Pharm Biotechnol
Pays: Netherlands
ID NLM: 100960530
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
08
2020
revised:
27
10
2020
accepted:
11
11
2020
pubmed:
22
12
2020
medline:
20
8
2021
entrez:
21
12
2020
Statut:
ppublish
Résumé
Stem cell therapy efficiently targets the brain for most neurological disorders like migraine, Parkinsonism, schizophrenia, Alzheimer's disease, and brain injury. The major obstacles in potential brain targeting are the physiological barriers like blood-brain-barrier and bloodcerebrospinal fluid barrier. The conventional injectable route or direct transplantation of stem cells results in brain injury and is less feasible clinically. The alternative to these invasive routes is the intranasal route that is non-invasive, easily repeatable technique and highly effective in brain targeting without crossing the blood-brain barrier. Extensive research has been undertaken for the delivery of stem cells to the brain via the intranasal route that holds great potential in overcoming the existing barriers. Nanotechnology is emerging as a novel interdisciplinary field in the arena of stem cell research. The combination of nanotechnology coupled with stem cell therapy has led to synergistic outcomes in diagnostic and therapeutic applications of neurological diseases. This review provides insights into stem cell-based nanotherapy for brain targeting via the intranasal route.
Identifiants
pubmed: 33342406
pii: CPB-EPUB-112538
doi: 10.2174/1389201021666201218130947
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1466-1481Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.